Please assess the completion status of the following clinical trial:

Trial Title: Atorvastatin Three Year Pediatric Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Heterozygous familial hypercholesterolemia, ages 6-15, LDL greater than 4 mmol/l~Exclusion Criteria:~* Active liver disease or hepatic dysfunction, or persistent elevations of serum transaminases exceeding three times the upper limit of normal (ULN).~Female of childbearing potential who is not using adequate contraceptive measures or any female who is pregnant or breastfeeding. Any female who becomes pregnant during study participation will be immediately discontinued from treatment and counseled appropriately about the in utero exposure.~Known hypersensitivities to HMG-CoA reductase inhibitors

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Atorvastatin (Type: EXPERIMENTAL): All subjects will be treated with atorvastatin

Based on this trial design, predict the completion outcome and termination type (if applicable).